Drug Delivery Platforms
•230 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (230)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Drug delivery platforms are highlighted as differentiators enabling scaled manufacturing.
|
$948.76B |
$1003.64
-0.41%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Drug delivery platform concepts (e.g., formulation/formulation technologies) are implied by delivery enhancements.
|
$82.77B |
$787.66
+2.74%
|
|
BDX
Becton, Dickinson and Company
BD develops drug delivery platforms and related biologic‑delivery solutions for therapeutics including GLP‑1s and wearables.
|
$48.95B |
$171.47
-1.57%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
ALNY employs drug delivery platforms (e.g., GalNAc conjugates) enabling targeted and durable RNAi delivery.
|
$43.24B |
$326.98
+2.61%
|
|
INSM
Insmed Incorporated
ARIKAYCE uses a liposomal inhalation drug-delivery platform (Pulmovance) and TPIP is an inhaled prodrug, making Drug Delivery Platforms a core Insmed technology.
|
$31.97B |
$149.81
+1.91%
|
|
BNTX
BioNTech SE
Drug Delivery Platforms cover mRNA delivery and related platforms used to deploy therapies.
|
$24.95B |
$103.82
+3.04%
|
|
PODD
Insulet Corporation
The insulin delivery platform functions as a drug delivery platform enabled by a medical device.
|
$17.09B |
$242.87
+0.42%
|
|
ASND
Ascendis Pharma A/S
TransCon is a proprietary drug-delivery platform enabling long-acting formulations, aligning with Drug Delivery Platforms.
|
$14.75B |
$241.24
+0.84%
|
|
JAZZ
Jazz Pharmaceuticals plc
Jazz's low-sodium formulation (Xywav) reflects a Drug Delivery Platform approach.
|
$11.47B |
$188.70
+1.09%
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.99B |
$137.05
-1.94%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
TRiM is a drug delivery platform enabling targeted siRNA delivery beyond the liver.
|
$8.84B |
$65.10
+1.56%
|
|
AXSM
Axsome Therapeutics, Inc.
MoSEIC drug-delivery platform powering Symbravo indicates reliance on Drug Delivery Platforms.
|
$8.27B |
$164.07
+0.01%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$8.23B |
$70.02
+0.89%
|
|
KRYS
Krystal Biotech, Inc.
Krystal's HSV-1 platform functions as a drug-delivery platform enabling redosable gene therapies across organs.
|
$7.68B |
$264.74
+0.36%
|
|
MTSR
Metsera, Inc.
HALO and MOMENTUM are proprietary drug-delivery platforms enabling extended half-life and oral peptide delivery, i.e., Drug Delivery Platforms.
|
$7.41B |
$70.53
+0.04%
|
|
GKOS
Glaukos Corporation
iDose TR represents a drug delivery platform delivering a sustained intraocular Travoprost formulation.
|
$6.63B |
$115.36
-2.03%
|
|
PTGX
Protagonist Therapeutics, Inc.
Platform-based drug delivery approach enabling peptide therapeutics.
|
$5.93B |
$94.92
+3.96%
|
|
CDTX
Cidara Therapeutics, Inc.
Cloudbreak is a drug delivery platform (Drug-Fc Conjugate) enabling extended half-life and targeted activity.
|
$5.61B |
$221.39
+0.00%
|
|
STVN
Stevanato Group S.p.A.
Provides Drug Delivery Platforms as integrated containment and delivery solutions for biologics.
|
$5.30B |
$17.48
+18.67%
|
|
SRRK
Scholar Rock Holding Corporation
Drug Delivery Platforms: platform-based approach enabling targeted modulation of growth factor signaling via antibodies.
|
$4.84B |
$47.45
+7.09%
|
|
ALKS
Alkermes plc
Proprietary drug delivery platforms (e.g., LinkeRx, NanoCrystal) used to create extended-release and rapid-dissolution formulations.
|
$4.83B |
$29.27
+0.24%
|
|
AKRO
Akero Therapeutics, Inc.
EFX is a biologic drug with a specialized delivery formulation (pre-filled syringe/lyophilized product), placing it squarely in the Drug Delivery Platforms category.
|
$4.37B |
$54.67
+0.04%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Amneal's focus on drug delivery platforms spans multiple complex dosage forms and delivery technologies.
|
$4.18B |
$13.29
-0.11%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Captisol and NITRICIL are platform technologies Ligand licenses/sells to enable drug solubility and tunable dosing, constituting drug delivery platforms.
|
$4.11B |
$208.88
+2.27%
|
|
INDV
Indivior Pharmaceuticals Inc
SUBLOCADE's extended-release delivery represents a drug delivery platform (monthly dosing), a core investable theme.
|
$4.02B |
$32.16
+4.16%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics' NDC platform and drug-conjugate strategy reflect a drug-delivery platform providing targeted payload delivery.
|
$3.75B |
$39.53
-1.47%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus leverages proprietary drug-delivery platforms, notably extended-release formulations, as a core differentiator for its CNS therapies.
|
$3.19B |
$55.57
+1.85%
|
|
DNLI
Denali Therapeutics Inc.
The TransportVehicle platform is a drug delivery platform designed to cross the blood-brain barrier to deliver biologics to the CNS.
|
$2.99B |
$20.36
+1.67%
|
|
LQDA
Liquidia Corporation
Liquidia's YUTREPIA is a PRINT-enabled inhaled treprostinil, a drug-delivery platform that enables high-dose, deep-lung delivery and differentiated pharmacokinetics.
|
$2.96B |
$34.40
+8.24%
|
|
BEAM
Beam Therapeutics Inc.
Beam uses lipid nanoparticle (LNP) delivery for in vivo base editing (BEAM-302, BEAM-301), i.e., a Drug Delivery Platform.
|
$2.78B |
$27.50
+1.01%
|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$2.35B |
$11.04
+2.65%
|
|
WVE
Wave Life Sciences Ltd.
PRISM delivers oligonucleotides via conjugates (e.g., GalNAc) and non-viral delivery, constituting a drug delivery platform.
|
$2.29B |
$13.71
+2.05%
|
|
DYN
Dyne Therapeutics, Inc.
Dyne's FORCE platform is a drug delivery platform enabling targeted payload delivery to muscle and CNS, making it a core product category.
|
$2.18B |
$15.22
+4.28%
|
|
ETNB
89bio, Inc.
The company relies on a glycoPEGylation-based drug delivery platform to extend half-life and dosing convenience, representing a Drug Delivery Platforms investable theme.
|
$2.17B |
$14.85
+0.07%
|
|
AVDL
Avadel Pharmaceuticals plc
Avadel uses a proprietary polymer-based extended-release drug-delivery platform to create once-nightly LUMRYZ.
|
$2.10B |
$21.66
+0.09%
|
|
IMNM
Immunome, Inc.
HC74 payload and linker optimization reflect a drug delivery platform approach.
|
$2.07B |
$22.51
+4.50%
|
|
SLNO
Soleno Therapeutics, Inc.
Drug Delivery Platforms reflects VYKAT XR's extended-release formulation and dosing advantage.
|
$2.05B |
$38.12
+1.05%
|
|
CLDX
Celldex Therapeutics, Inc.
Drug delivery platforms and subcutaneous formulations are part of Celldex's formulation strategy.
|
$1.96B |
$29.53
+2.04%
|
|
ZYME
Zymeworks Inc.
Drug Delivery Platforms underpin ADC and multispecific payload engineering and delivery.
|
$1.89B |
$25.23
+3.17%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MindMed's use of a proprietary oral-dispensing drug-delivery technology constitutes a Drug Delivery Platform.
|
$1.75B |
$17.80
+2474.86%
|
|
ANIP
ANI Pharmaceuticals, Inc.
Development of drug delivery platforms (e.g., Cortrophin Gel pre-filled syringe) demonstrates ANI's drug delivery technology differentiators.
|
$1.72B |
$76.62
+0.69%
|
|
NBTX
Nanobiotix S.A.
Curadigm and Oocuity are nanoparticle-based platforms aimed at drug delivery and neurally targeted effects, aligning with Drug Delivery Platforms.
|
$1.70B |
$36.04
+17.85%
|
|
SRPT
Sarepta Therapeutics, Inc.
Drug Delivery Platforms underpin Sarepta's delivery of gene therapies and RNAi assets.
|
$1.69B |
$16.08
+1.32%
|
|
NUVB
Nuvation Bio Inc.
NUV-1511 is based on a Drug-Delivery Platform (DDC), directly describing a drug delivery platform product.
|
$1.63B |
$4.74
+8.72%
|
|
NVAX
Novavax, Inc.
Matrix-M is a proprietary vaccine adjuvant/drug-delivery platform used across Novavax's vaccine programs, constituting a major platform technology.
|
$1.61B |
$9.90
+4.32%
|
|
NTLA
Intellia Therapeutics, Inc.
Proprietary drug-delivery platform (LNP) enabling in vivo gene editing across programs.
|
$1.60B |
$13.81
+1.54%
|
|
OCS
Oculis Holding AG
OPTIREACH is a drug delivery platform enabling topical therapies to reach the posterior segment.
|
$1.55B |
$27.71
+0.53%
|
|
PHVS
Pharvaris N.V.
Pharvaris emphasizes oral delivery with injectable-like efficacy, indicating a Drug Delivery Platforms orientation.
|
$1.47B |
$26.65
-0.47%
|
|
PVLA
Palvella Therapeutics, Inc.
QTORIN represents a drug delivery platform for localized, topical therapy, a major category in pharmaceutical technology and patient-specific treatments.
|
$1.47B |
$131.44
-0.89%
|
|
KOD
Kodiak Sciences Inc.
ABC/ABCD platforms are drug delivery technologies enabling sustained ocular release and extended durability.
|
$1.42B |
$26.83
+1.48%
|
|
NKTR
Nektar Therapeutics
PEGylation is a drug-delivery platform approach used to optimize pharmacokinetics and dosing.
|
$1.35B |
$71.00
+4.24%
|
|
VIR
Vir Biotechnology, Inc.
PRO-XTEN masking platform represents a drug delivery platform intended to improve safety and therapeutic index.
|
$1.33B |
$9.56
+7.30%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Core platform technology (Durasert E) used for sustained ocular drug delivery.
|
$1.24B |
$18.03
-1.58%
|
|
CAPR
Capricor Therapeutics, Inc.
StealthX is described as an exosome-based drug delivery platform for targeted cargo delivery.
|
$1.17B |
$25.51
-1.28%
|
|
BHVN
Biohaven Ltd.
MoDE/TRAP and related platforms constitute drug-delivery platforms enabling targeted degradation of extracellular proteins.
|
$1.12B |
$10.61
-0.56%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$1.10B |
$11.36
+1.88%
|
|
INBX
Inhibrx Biosciences, Inc.
Drug delivery platform technology underpinning biologic therapies.
|
$1.08B |
$74.40
+0.09%
|
|
PGEN
Precigen, Inc.
Drug Delivery Platforms tag applies to platform-based delivery mechanisms like AdenoVerse and UltraCAR-T.
|
$1.06B |
$3.56
+5.48%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX is using a drug delivery platform (PEP) to extend action of peptides, enabling less frequent dosing, fitting Drug Delivery Platforms.
|
$1.05B |
$31.39
+2.77%
|
|
CVAC
CureVac N.V.
Drug Delivery Platforms captures CureVac's proprietary LNP delivery systems and thermostable formulations integral to its mRNA programs.
|
$1.05B |
$4.66
|
|
XERS
Xeris Biopharma Holdings, Inc.
Xeris's XeriSol and XeriJect drug-delivery platforms enable stable, ready-to-use injectable formulations, a core differentiator.
|
$1.01B |
$6.07
+2.10%
|
|
SVRA
Savara Inc.
Delivery via inhalation (Drug Delivery Platform) is a core aspect of MOLBREEVI's administration method.
|
$1.00B |
$5.58
-3.79%
|
|
GHRS
GH Research PLC
GH Research employs an inhalable drug delivery approach for GH001, representing a Drug Delivery Platforms capability.
|
$991.85M |
$15.99
+4.51%
|
|
VERV
Verve Therapeutics, Inc.
Verve's platform GalNAc-LNP is a proprietary drug delivery system used to target liver cells for gene-editing therapies.
|
$988.30M |
$11.13
|
|
PCRX
Pacira BioSciences, Inc.
Pacira's pMVL-based Drug Delivery Platforms enable extended-release formulations used in EXPAREL and ZILRETTA.
|
$983.47M |
$22.89
+3.57%
|
|
TBPH
Theravance Biopharma, Inc.
YUPELRI's nebulized delivery represents a drug delivery platform differentiator for a respiratory therapy.
|
$969.96M |
$19.09
-0.86%
|
|
ABUS
Arbutus Biopharma Corporation
Their LNP delivery technology is a drug delivery platform underpinning their RNAi assets.
|
$948.91M |
$4.58
-7.58%
|
|
URGN
UroGen Pharma Ltd.
RTGel is a drug-delivery platform used by UroGen for localized, extended-release therapy.
|
$943.67M |
$20.13
+6.96%
|
|
OPK
OPKO Health, Inc.
Entera Bio collaboration for oral formulation indicates an emphasis on drug delivery platforms.
|
$921.24M |
$1.20
+0.84%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$919.51M |
$4.16
-3.03%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Drug Delivery Platforms captures Amphastar's proprietary delivery systems for injectables, inhalation, and intranasal therapies.
|
$917.21M |
$19.96
+0.66%
|
|
CTMX
CytomX Therapeutics, Inc.
PROBODY is a drug delivery platform designed to localize activity to tumors, fitting Drug Delivery Platforms.
|
$836.11M |
$5.07
+5.41%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
Phathom is pursuing an orally disintegrating tablet (ODT) formulation and other delivery innovations for VOQUEZNA, aligning with the drug delivery platforms investable theme.
|
$786.79M |
$11.07
+0.18%
|
|
PRME
Prime Medicine, Inc.
Leverages a drug delivery platform (universal liver LNP with GalNAc targeting) to enable in vivo gene editing.
|
$743.70M |
$4.12
-2.60%
|
|
HYEX
Healthy Extracts Inc.
Exclusive rights to an oral delivery technology for nutritional supplements, a distinctive platform that differentiates the company’s product delivery.
|
$718.60M |
$2.35
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$624.33M |
$22.78
+4.16%
|
|
SRDX
Surmodics, Inc.
The company provides proprietary drug-delivery platform technologies used on medical devices (SurVeil DCB) and related platforms.
|
$614.58M |
$42.98
|
|
MGTX
MeiraGTx Holdings plc
Riboswitch platform represents a drug delivery platform enabling regulated transgene expression, a core technology.
|
$607.38M |
$7.40
-1.99%
|
|
KE
Kimball Electronics, Inc.
Drug delivery platforms are a targeted medical technology offering within KE's Medical CMO scope.
|
$597.99M |
$24.57
+1.74%
|
|
DSGN
Design Therapeutics, Inc.
GeneTAC platform implies a drug delivery/modulation approach, aligning with a Drug Delivery Platforms category.
|
$590.55M |
$10.37
+3.70%
|
|
REPL
Replimune Group, Inc.
RPx platform functions as a drug delivery platform enabling multi-gene payload immunotherapies.
|
$568.71M |
$7.26
+1.32%
|
|
ENGN
enGene Holdings Inc.
DDX platform is a drug delivery technology enabling localized genetic medicines, a distinct product category.
|
$498.61M |
$9.75
+0.93%
|
|
ANRO
Alto Neuroscience, Inc.
Drug delivery platform to enable targeted or improved administration of Alto's CNS therapeutics (e.g., transdermal PDE4 inhibitor).
|
$495.50M |
$19.34
+5.71%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$477.74M |
$12.53
+5.74%
|
|
ADCT
ADC Therapeutics S.A.
ADCT emphasizes a proprietary Drug Delivery Platform powering its ADC payloads and conjugation chemistries.
|
$477.00M |
$4.25
+5.06%
|
|
ZVRA
Zevra Therapeutics, Inc.
LAT platform enables prodrug drug delivery platforms, representing a proprietary drug-delivery platform technology.
|
$466.48M |
$8.48
+2.05%
|
|
LRMR
Larimar Therapeutics, Inc.
The CPP-based delivery platform is a core technology used to deliver nomlabofusp, i.e., Drug Delivery Platforms.
|
$466.47M |
$5.44
-1.27%
|
|
RGNX
REGENXBIO Inc.
NAV platform involves drug delivery platform technology.
|
$461.70M |
$9.13
+5.06%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage emphasizes a drug delivery platform and formulation (cryopreserved thaw-and-inject formulations) enabling scalable, ready-to-administer cell therapies.
|
$445.29M |
$1.95
+3.17%
|
|
AQST
Aquestive Therapeutics, Inc.
Aquestive's PharmFilm drug-delivery platform enables non-invasive, thin-film administration of complex molecules; Anaphylm and Libervant employ this platform.
|
$435.79M |
$4.38
+6.19%
|
|
FLGT
Fulgent Genetics, Inc.
Drug delivery platforms including nanoencapsulation.
|
$432.46M |
$14.02
+1.67%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT's Therapeutic Vector Evolution platform constitutes a drug delivery platform enabling targeted, durable gene therapy delivery.
|
$417.05M |
$8.93
+5.50%
|
|
CYBN
Cybin Inc.
CYB004 utilizes a deuterated drug delivery approach including an inhalation platform, indicating a Drug Delivery Platforms capability.
|
$413.12M |
$8.30
+1.53%
|
|
PRTC
PureTech Health plc
Glyph platform is a drug-delivery technology enabling oral administration of therapies.
|
$409.41M |
$17.65
+2.32%
|
|
DMAC
DiaMedica Therapeutics Inc.
DM199 represents a drug-delivery/therapeutic platform with IV administration and ongoing manufacturing development.
|
$401.62M |
$7.78
+0.91%
|
|
AURA
Aura Biosciences, Inc.
Aura's VDC platform is a drug delivery platform enabling targeted, light-activated therapy.
|
$393.22M |
$6.16
-2.69%
|
|
CATX
Perspective Therapeutics, Inc.
Developing a drug-delivery platform around the 212Pb radiopharmaceuticals and regional finishing capabilities.
|
$391.37M |
$5.28
+2.03%
|
|
LXEO
Lexeo Therapeutics, Inc. Common Stock
Uses a drug delivery platform (AAV vectors) to deliver genes, constituting a drug delivery platform business line.
|
$390.97M |
$7.23
+2.26%
|
|
BCYC
Bicycle Therapeutics plc
Platform enables targeted delivery and payload conjugation for therapeutics (drug delivery platform).
|
$390.20M |
$5.62
+2.27%
|
|
MNPR
Monopar Therapeutics Inc.
MNPR-101 platform represents a drug delivery platform for radiopharmaceuticals, enabling targeted delivery and radionuclide conjugation.
|
$380.87M |
$56.59
-8.33%
|
Showing page 1 of 3 (230 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
